Meihan Liu
Nanchong, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
CD168 in lung adenocarcinoma: prognostic relevance, immune feature associations, and MAPK/ERK pathway enrichment.
Journal: Medical oncology (Northwood, London, England)
Published: October 29, 2025
BANF1 as a potential prognostic biomarker associated with tumor-intrinsic programs and a complex immune landscape in lung adenocarcinoma.
Journal: Discover oncology
Published: September 19, 2025
Comprehensive analysis identifies PKMYT1 as an oncogene and potential prognostic and immunological biomarker in lung adenocarcinoma.
Journal: Translational cancer research
Published: July 27, 2025
Multidimensional analysis of hsa-miR-140-3p and CKS1B correlation via the MAPK/ERK pathway in lung adenocarcinoma progression.
Journal: Discover oncology
Published: June 18, 2025
GNG7 as a tumor-suppressor gene in lung adenocarcinoma: implications for prognosis and immune-based therapies.
Journal: Frontiers in oncology
Published: March 06, 2025
Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma.
Journal: Frontiers in genetics
Published: November 20, 2024
Comprehensive analysis reveals that P4HA3 is a prognostic and diagnostic gastric cancer biomarker that can predict immunotherapy efficacy.
Journal: Scientific reports
Published: February 11, 2024
Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma.
Journal: Scientific reports
Published: July 30, 2021
Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
Journal: Journal of cancer research and clinical oncology
Published: June 14, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026